Symbols / TOVX $0.19 +10.10%
TOVX Chart
About
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.88M |
| Enterprise Value | 1.74M | Income | -26.19M | Sales | — |
| Book/sh | 0.65 | Cash/sh | 0.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | 0.09 | Forward P/E | -0.96 | PEG | — |
| P/S | — | P/B | 0.29 | P/C | — |
| EV/EBITDA | -0.11 | EV/Sales | — | Quick Ratio | 0.85 |
| Current Ratio | 0.90 | Debt/Eq | 40.99 | LT Debt/Eq | — |
| EPS (ttm) | -2.08 | EPS next Y | -0.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -29.21% |
| ROE | -166.96% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 35.69M |
| Shs Float | 33.19M | Short Float | 17.14% | Short Ratio | 0.41 |
| Short Interest | — | 52W High | 1.50 | 52W Low | 0.16 |
| Beta | 0.52 | Avg Volume | 10.25M | Volume | 20.79M |
| Target Price | $4.00 | Recom | Buy | Prev Close | $0.18 |
| Price | $0.19 | Change | 10.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.19
Latest analyst target
3. DCF / Fair value
$-2.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.19
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-08 | down | Maxim Group | Buy → Hold | — |
| 2024-11-13 | main | Maxim Group | Buy → Buy | $6 |
- Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan hu, 12 Mar 2026 12
- Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Mon, 29 Dec 2025 08
- Gut-targeted SYN-020 licensed to treat metabolic and inflammatory disease - Stock Titan Wed, 18 Feb 2026 08
- TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus hu, 12 Mar 2026 12
- TOVX: Advanced clinical pipeline, secured SYN-020 licensing, and extended cash runway into 2027 - TradingView hu, 12 Mar 2026 12
- Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next? - TechStock² Fri, 24 Oct 2025 07
- Why Is Theriva Biologics Stock Gaining Monday? - Benzinga Mon, 29 Dec 2025 08
- Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView hu, 12 Mar 2026 12
- Theriva Biologics (TOVX) Addresses Unusual Stock Activity - GuruFocus Fri, 24 Oct 2025 07
- Theriva Biologics files prospectus for up to $4 million at-the-market offering - Investing.com Fri, 24 Oct 2025 07
- Theriva (NYSE American: TOVX) says no undisclosed material updates amid unusual trading - Stock Titan Fri, 24 Oct 2025 07
- Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last? - TechStock² Wed, 15 Oct 2025 07
- TOVX SEC Filings - THERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 25 Feb 2026 07
- TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus hu, 08 May 2025 07
- $4.0M Gross Proceeds: Theriva Biologics' Warrant Inducement Issues 14.72M New Warrants - Stock Titan hu, 16 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 246.00 | -2.77K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.08 | 0.07 |
| NormalizedEBITDA | -23.97M | -12.37M | -21.30M | -21.45M |
| TotalUnusualItems | 25.00K | -6.92M | 3.00K | -41.00K |
| TotalUnusualItemsExcludingGoodwill | 25.00K | -6.92M | 3.00K | -41.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -23.74M | -25.65M | -18.35M | -19.68M |
| ReconciledDepreciation | 108.00K | 137.00K | 135.00K | 85.00K |
| EBITDA | -23.94M | -19.29M | -21.30M | -21.50M |
| EBIT | -24.05M | -19.43M | -21.43M | -21.58M |
| NetInterestIncome | 287.00K | 697.00K | 1.44M | 512.00K |
| InterestIncome | 287.00K | 697.00K | 1.44M | 512.00K |
| NormalizedIncome | -23.76M | -18.73M | -18.35M | -19.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -23.74M | -25.65M | -18.35M | -19.68M |
| TotalExpenses | 24.05M | 19.43M | 21.43M | 21.58M |
| TotalOperatingIncomeAsReported | -24.05M | -26.35M | -21.43M | -21.58M |
| DilutedAverageShares | 12.14M | 1.35M | 644.28K | 613.09K |
| BasicAverageShares | 12.14M | 1.35M | 644.28K | 613.09K |
| DilutedEPS | -2.08 | -19.03 | -28.48 | -32.75 |
| BasicEPS | -2.08 | -19.03 | -28.48 | -32.75 |
| DilutedNIAvailtoComStockholders | -25.25M | -25.65M | -18.35M | -20.02M |
| NetIncomeCommonStockholders | -25.25M | -25.65M | -18.35M | -20.02M |
| OtherunderPreferredStockDividend | 1.51M | 0.00 | 0.00 | 340.00K |
| PreferredStockDividends | 1.52M | |||
| NetIncome | -23.74M | -25.65M | -18.35M | -19.68M |
| MinorityInterests | 0.00 | 1.00K | ||
| NetIncomeIncludingNoncontrollingInterests | -23.74M | -25.65M | -18.35M | -19.68M |
| NetIncomeContinuousOperations | -23.74M | -25.65M | -18.35M | -19.68M |
| TaxProvision | 0.00 | 0.00 | -1.64M | -1.43M |
| PretaxIncome | -23.74M | -25.65M | -19.99M | -21.11M |
| OtherIncomeExpense | 25.00K | -6.92M | 3.00K | -41.00K |
| SpecialIncomeCharges | 0.00 | -6.92M | 0.00 | |
| WriteOff | 0.00 | 1.32M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 5.59M | 0.00 | |
| GainOnSaleOfSecurity | 25.00K | -4.00K | 3.00K | -41.00K |
| NetNonOperatingInterestIncomeExpense | 287.00K | 697.00K | 1.44M | 512.00K |
| InterestIncomeNonOperating | 287.00K | 697.00K | 1.44M | 512.00K |
| OperatingIncome | -24.05M | -19.43M | -21.43M | -21.58M |
| OperatingExpense | 24.05M | 19.43M | 21.43M | 21.58M |
| ResearchAndDevelopment | 8.60M | 12.03M | 14.31M | 11.72M |
| SellingGeneralAndAdministration | 15.45M | 7.40M | 7.12M | 9.86M |
| GeneralAndAdministrativeExpense | 15.45M | 7.40M | 7.12M | 9.86M |
| OtherGandA | 15.45M | 7.40M | 7.12M | 9.86M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 28.81K | 28.81K | 28.80K | 9.00 |
| OrdinarySharesNumber | 35.69M | 2.78M | 685.92K | 604.96K |
| ShareIssued | 35.69M | 2.81M | 714.73K | 633.76K |
| TotalDebt | 2.63M | 1.56M | 2.15M | 1.68M |
| TangibleBookValue | -4.24M | 1.71M | 11.51M | 27.16M |
| InvestedCapital | 17.11M | 19.22M | 37.19M | 52.11M |
| WorkingCapital | 7.45M | 8.70M | 20.66M | 38.46M |
| NetTangibleAssets | -4.24M | 1.71M | 14.24M | 29.89M |
| CapitalLeaseObligations | 901.00K | 1.41M | 1.93M | 1.40M |
| CommonStockEquity | 15.38M | 19.07M | 36.96M | 51.83M |
| PreferredStockEquity | 2.73M | 2.73M | ||
| TotalCapitalization | 17.05M | 19.16M | 39.86M | 54.78M |
| TotalEquityGrossMinorityInterest | 15.38M | 19.07M | 39.70M | 54.56M |
| MinorityInterest | 0.00 | |||
| StockholdersEquity | 15.38M | 19.07M | 39.70M | 54.56M |
| GainsLossesNotAffectingRetainedEarnings | 755.00K | -1.18M | 32.00K | -679.00K |
| OtherEquityAdjustments | 755.00K | -1.18M | 32.00K | -679.00K |
| TreasuryStock | 288.00K | 288.00K | 288.00K | 288.00K |
| RetainedEarnings | -358.71M | -334.97M | -309.32M | -290.97M |
| AdditionalPaidInCapital | 373.59M | 355.50M | 346.54M | 343.75M |
| CapitalStock | 34.00K | 3.00K | 2.73M | 2.75M |
| CommonStock | 34.00K | 3.00K | 1.00K | 16.00K |
| PreferredStock | 0.00 | 2.73M | 2.73M | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 22.86M | 16.29M | 15.52M | 17.30M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 12.84M | 8.70M | 8.78M | 10.24M |
| OtherNonCurrentLiabilities | 10.00M | 6.97M | 6.27M | 7.21M |
| NonCurrentDeferredLiabilities | 815.00K | 762.00K | 906.00K | 1.62M |
| NonCurrentDeferredTaxesLiabilities | 815.00K | 762.00K | 906.00K | 1.62M |
| LongTermDebtAndCapitalLeaseObligation | 2.02M | 965.00K | 1.60M | 1.41M |
| LongTermCapitalLeaseObligation | 352.00K | 873.00K | 1.44M | 1.19M |
| LongTermDebt | 1.67M | 92.00K | 162.00K | 221.00K |
| CurrentLiabilities | 10.01M | 7.58M | 6.74M | 7.06M |
| OtherCurrentLiabilities | 2.97M | |||
| CurrentDeferredLiabilities | 1.68M | 1.61M | 906.00K | 0.00 |
| CurrentDeferredTaxesLiabilities | 1.68M | 1.61M | 906.00K | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 606.00K | 600.00K | 550.00K | 273.00K |
| CurrentCapitalLeaseObligation | 549.00K | 539.00K | 487.00K | 216.00K |
| CurrentDebt | 57.00K | 61.00K | 63.00K | 57.00K |
| OtherCurrentBorrowings | 57.00K | 61.00K | 63.00K | 57.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 153.00K | 187.00K | 127.00K | 87.00K |
| PayablesAndAccruedExpenses | 7.58M | 5.18M | 5.16M | 3.73M |
| CurrentAccruedExpenses | 6.57M | 4.33M | 4.38M | 2.81M |
| Payables | 1.01M | 859.00K | 770.00K | 915.00K |
| AccountsPayable | 1.01M | 859.00K | 770.00K | 915.00K |
| TotalAssets | 38.24M | 35.35M | 55.22M | 71.86M |
| TotalNonCurrentAssets | 20.77M | 19.07M | 27.82M | 26.34M |
| OtherNonCurrentAssets | 128.00K | 171.00K | 180.00K | 122.00K |
| NonCurrentPrepaidAssets | 23.00K | 23.00K | ||
| GoodwillAndOtherIntangibleAssets | 19.62M | 17.36M | 25.45M | 24.68M |
| OtherIntangibleAssets | 19.62M | 17.36M | 19.75M | 19.15M |
| Goodwill | 0.00 | 5.70M | 5.53M | 0.00 |
| NetPPE | 1.02M | 1.54M | 2.18M | 1.54M |
| AccumulatedDepreciation | -966.00K | -935.00K | -1.00M | -865.00K |
| GrossPPE | 1.99M | 2.48M | 3.18M | 2.41M |
| Leases | 94.00K | 94.00K | 94.00K | 94.00K |
| OtherProperties | 1.25M | 1.66M | 2.18M | 1.41M |
| MachineryFurnitureEquipment | 650.00K | 719.00K | 913.00K | 908.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 17.47M | 16.28M | 27.40M | 45.52M |
| PrepaidAssets | 576.00K | 1.35M | 2.29M | 3.50M |
| Receivables | 3.83M | 3.32M | 1.94M | 231.00K |
| OtherReceivables | 452.00K | 144.00K | ||
| TaxesReceivable | 3.38M | 3.32M | 1.94M | 87.00K |
| CashCashEquivalentsAndShortTermInvestments | 13.06M | 11.61M | 23.18M | 41.79M |
| CashAndCashEquivalents | 13.06M | 11.61M | 23.18M | 41.79M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.70M | -16.94M | -19.20M | -19.20M |
| RepurchaseOfCapitalStock | 0.00 | -288.00K | 0.00 | |
| RepaymentOfDebt | -70.00K | -67.00K | -75.00K | -1.38M |
| IssuanceOfDebt | 1.51M | 0.00 | ||
| IssuanceOfCapitalStock | 13.52M | 5.56M | 2.22M | 2.73M |
| CapitalExpenditure | -35.00K | -1.00K | -202.00K | -116.00K |
| EndCashPosition | 13.10M | 11.71M | 23.28M | 41.88M |
| BeginningCashPosition | 11.71M | 23.28M | 41.88M | 67.33M |
| EffectOfExchangeRateChanges | -92.00K | -132.00K | -33.00K | -32.00K |
| ChangesInCash | 1.49M | -11.44M | -18.57M | -25.41M |
| FinancingCashFlow | 18.19M | 5.50M | 625.00K | -1.93M |
| CashFlowFromContinuingFinancingActivities | 18.19M | 5.50M | 625.00K | -1.93M |
| NetOtherFinancingCharges | -713.00K | -1.52M | -3.00M | |
| ProceedsFromStockOptionExercised | 3.95M | 0.00 | 0.00 | 8.04M |
| NetPreferredStockIssuance | 0.00 | 2.73M | 0.00 | |
| PreferredStockIssuance | 0.00 | 2.73M | 0.00 | |
| NetCommonStockIssuance | 13.52M | 5.56M | 2.22M | -288.00K |
| CommonStockPayments | 0.00 | -288.00K | 0.00 | |
| CommonStockIssuance | 13.52M | 5.56M | 2.22M | 0.00 |
| NetIssuancePaymentsOfDebt | 1.44M | -67.00K | -75.00K | -1.38M |
| NetLongTermDebtIssuance | 1.44M | -67.00K | -75.00K | -1.38M |
| LongTermDebtPayments | -70.00K | -67.00K | -75.00K | -1.38M |
| LongTermDebtIssuance | 1.51M | 0.00 | ||
| InvestingCashFlow | -35.00K | -1.00K | -202.00K | -4.40M |
| CashFlowFromContinuingInvestingActivities | -35.00K | -1.00K | -202.00K | -4.40M |
| NetBusinessPurchaseAndSale | 0.00 | -4.28M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -4.28M | 0.00 | |
| NetPPEPurchaseAndSale | -35.00K | -1.00K | -202.00K | -116.00K |
| PurchaseOfPPE | -35.00K | -1.00K | -202.00K | -116.00K |
| OperatingCashFlow | -16.67M | -16.94M | -19.00M | -19.08M |
| CashFlowFromContinuingOperatingActivities | -16.67M | -16.94M | -19.00M | -19.08M |
| ChangeInWorkingCapital | -3.06M | 726.00K | 2.31M | -806.00K |
| ChangeInOtherWorkingCapital | 333.00K | 110.00K | ||
| ChangeInOtherCurrentLiabilities | -562.00K | -482.00K | -422.00K | -124.00K |
| ChangeInOtherCurrentAssets | 166.00K | |||
| ChangeInPayablesAndAccruedExpense | -2.95M | 295.00K | 1.42M | -319.00K |
| ChangeInAccruedExpense | -3.02M | 172.00K | 1.57M | 66.00K |
| ChangeInPayable | 69.00K | 123.00K | -157.00K | -385.00K |
| ChangeInAccountPayable | 69.00K | 123.00K | -157.00K | -385.00K |
| ChangeInPrepaidAssets | 456.00K | 913.00K | 1.31M | -363.00K |
| OtherNonCashItems | 9.55M | 1.15M | -2.00M | 2.27M |
| StockBasedCompensation | 654.00K | 671.00K | 552.00K | 475.00K |
| AssetImpairmentCharge | 0.00 | 6.92M | 0.00 | |
| DeferredTax | -188.00K | -888.00K | -1.64M | -1.43M |
| DeferredIncomeTax | -188.00K | -888.00K | -1.64M | -1.43M |
| DepreciationAmortizationDepletion | 108.00K | 137.00K | 135.00K | 85.00K |
| DepreciationAndAmortization | 108.00K | 137.00K | 135.00K | 85.00K |
| Depreciation | 108.00K | 137.00K | 135.00K | 85.00K |
| OperatingGainsLosses | 1.00K | |||
| NetIncomeFromContinuingOperations | -23.74M | -25.65M | -18.35M | -19.68M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TOVX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|